S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:TECH

Bio-Techne Competitors

$361.69
-3.37 (-0.92 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$358.98
Now: $361.69
$368.45
50-Day Range
$318.43
MA: $362.84
$411.00
52-Week Range
$155.17
Now: $361.69
$414.99
Volume245,717 shs
Average Volume194,645 shs
Market Capitalization$14.03 billion
P/E Ratio57.87
Dividend Yield0.35%
Beta1.13

Competitors

Bio-Techne (NASDAQ:TECH) Vs. TMO, ILMN, A, MTD, BIO, and WAT

Should you be buying TECH stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Bio-Techne, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), and Waters (WAT).

Thermo Fisher Scientific (NYSE:TMO) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Bio-Techne's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion6.98$3.70 billion$12.3536.44
Bio-Techne$738.69 million19.00$229.30 million$3.8693.70

Thermo Fisher Scientific has higher revenue and earnings than Bio-Techne. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Thermo Fisher Scientific and Bio-Techne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific041502.79
Bio-Techne04602.60

Thermo Fisher Scientific currently has a consensus target price of $529.6667, indicating a potential upside of 17.68%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities research analysts clearly believe Thermo Fisher Scientific is more favorable than Bio-Techne.

Profitability

This table compares Thermo Fisher Scientific and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Bio-Techne32.69%12.20%8.09%

Dividends

Thermo Fisher Scientific pays an annual dividend of $0.88 per share and has a dividend yield of 0.2%. Bio-Techne pays an annual dividend of $1.28 per share and has a dividend yield of 0.4%. Thermo Fisher Scientific pays out 7.1% of its earnings in the form of a dividend. Bio-Techne pays out 33.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has raised its dividend for 3 consecutive years and Bio-Techne has raised its dividend for 1 consecutive years.

Volatility and Risk

Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Summary

Thermo Fisher Scientific beats Bio-Techne on 10 of the 17 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 0.4% of Illumina shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Illumina and Bio-Techne's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion18.09$1.00 billion$6.5766.88
Bio-Techne$738.69 million19.00$229.30 million$3.8693.70

Illumina has higher revenue and earnings than Bio-Techne. Illumina is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Illumina and Bio-Techne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina38702.22
Bio-Techne04602.60

Illumina presently has a consensus target price of $365.3158, indicating a potential downside of 16.86%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Techne is more favorable than Illumina.

Profitability

This table compares Illumina and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
Bio-Techne32.69%12.20%8.09%

Volatility & Risk

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Summary

Illumina beats Bio-Techne on 8 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Bio-Techne (NASDAQ:TECH) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are held by institutional investors. 3.8% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Agilent Technologies and Bio-Techne's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion6.98$719 million$3.2837.22
Bio-Techne$738.69 million19.00$229.30 million$3.8693.70

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Agilent Technologies and Bio-Techne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies0101602.62
Bio-Techne04602.60

Agilent Technologies presently has a consensus target price of $100.4619, indicating a potential downside of 17.70%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Agilent Technologies.

Profitability

This table compares Agilent Technologies and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
Bio-Techne32.69%12.20%8.09%

Dividends

Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Bio-Techne pays an annual dividend of $1.28 per share and has a dividend yield of 0.4%. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Bio-Techne pays out 33.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 1 consecutive years and Bio-Techne has raised its dividend for 1 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and lower payout ratio.

Risk & Volatility

Agilent Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Mettler-Toledo International (NYSE:MTD) and Bio-Techne (NASDAQ:TECH) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Mettler-Toledo International and Bio-Techne's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion8.68$561.11 million$22.7749.01
Bio-Techne$738.69 million19.00$229.30 million$3.8693.70

Mettler-Toledo International has higher revenue and earnings than Bio-Techne. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mettler-Toledo International and Bio-Techne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International47101.75
Bio-Techne04602.60

Mettler-Toledo International presently has a consensus target price of $868.0833, indicating a potential downside of 22.22%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Techne is more favorable than Mettler-Toledo International.

Profitability

This table compares Mettler-Toledo International and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Bio-Techne32.69%12.20%8.09%

Volatility & Risk

Mettler-Toledo International has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Summary

Bio-Techne beats Mettler-Toledo International on 9 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Volatility & Risk

Bio-Rad Laboratories has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Insider and Institutional Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Bio-Rad Laboratories and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Bio-Techne32.69%12.20%8.09%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bio-Rad Laboratories and Bio-Techne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00403.00
Bio-Techne04602.60

Bio-Rad Laboratories presently has a consensus target price of $646.00, indicating a potential upside of 10.52%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Techne.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Bio-Techne's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.54$1.76 billion$7.0682.79
Bio-Techne$738.69 million19.00$229.30 million$3.8693.70

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Bio-Techne (NASDAQ:TECH) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Bio-Techne has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Comparatively, 1.5% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Bio-Techne and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Waters22.61%-349.31%21.11%

Analyst Ratings

This is a summary of current ratings and recommmendations for Bio-Techne and Waters, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne04602.60
Waters58101.71

Bio-Techne presently has a consensus price target of $352.30, indicating a potential downside of 2.60%. Waters has a consensus price target of $219.4545, indicating a potential downside of 19.87%. Given Bio-Techne's stronger consensus rating and higher possible upside, equities analysts plainly believe Bio-Techne is more favorable than Waters.

Earnings & Valuation

This table compares Bio-Techne and Waters' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million19.00$229.30 million$3.8693.70
Waters$2.41 billion7.06$592.20 million$8.9930.46

Waters has higher revenue and earnings than Bio-Techne. Waters is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats Waters on 10 of the 14 factors compared between the two stocks.


Bio-Techne Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$450.08-0.3%$178.38 billion$25.54 billion36.89Dividend Increase
Illumina logo
ILMN
Illumina
1.7$439.41-1.5%$64.11 billion$3.54 billion101.95
Agilent Technologies logo
A
Agilent Technologies
1.8$122.07-0.0%$37.28 billion$5.34 billion53.07Buyback Announcement
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,116.05-0.6%$26.12 billion$3.01 billion46.95
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$584.50-0.4%$17.44 billion$2.31 billion5.00
Waters logo
WAT
Waters
1.5$273.88-1.6%$16.99 billion$2.41 billion34.11
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$286.14-2.1%$14.24 billion$2.62 billion47.69Analyst Upgrade
Insider Selling
News Coverage
PerkinElmer logo
PKI
PerkinElmer
1.9$126.09-0.1%$14.12 billion$2.88 billion34.26
Bruker logo
BRKR
Bruker
2.1$60.98-3.0%$9.34 billion$2.07 billion59.78News Coverage
Gap Down
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$30.57-2.0%$5.51 billion$90.89 million-109.17Insider Selling
Gap Down
Luminex logo
LMNX
Luminex
1.8$32.52-1.4%$1.51 billion$334.64 million83.39
Fluidigm logo
FLDM
Fluidigm
1.8$4.60-4.8%$340.95 million$117.24 million-6.87Gap Down
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.4$4.39-1.4%$171.11 million$116.18 million-24.39Gap Up
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$4.35-4.8%$44.31 million$420,000.00-1.64News Coverage
Gap Down
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.